Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT7 | O95251 | 1/20 | 0.44 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 4/20 | 0.36 |
| ▸ | KAT5 | Q92993 | 3/20 | 0.36 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.35 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.35 |
| ▸ | KAT8 | Q9H7Z6 | 3/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24558458 | 1.00 | KAT7 (0.44) | KAT7PAK1KAT6AKAT5SETD7 | |
| SCHEMBL29825436 | 0.93 | KAT7 (0.43) | KAT7PAK1KAT6AKAT5SETD7 | |
| SCHEMBL23512948 | 0.93 | KAT7 (0.43) | KAT7PAK1KAT6AKAT5SETD7 | |
| SCHEMBL24558323 | 0.90 | KAT7 (0.40) | KAT7PAK1SETD7USP30KAT8 | |
| SCHEMBL23512568 | 0.89 | KAT7 (0.44) | KAT7PAK1KAT6AKAT5POLB | |
| SCHEMBL24558470 | 0.89 | KAT7 (0.39) | KAT7PAK1SETD7USP30ABHD6 | |
| SCHEMBL23512653 | 0.89 | KAT7 (0.44) | KAT7PAK1KAT6AKAT5POLB | |
| SCHEMBL23512859 | 0.88 | KAT7 (0.42) | KAT7PAK1KAT6AKAT5SETD7 | |
| SCHEMBL29693106 | 0.88 | KAT7 (0.42) | KAT7PAK1KAT6AKAT5SETD7 | |
| SCHEMBL26879127 | 0.88 | KAT7 (0.42) | KAT7PAK1KAT6AKAT5SETD7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | ASTRAZENECA AB (SE) | 2025-09-09 | — | — | US | disclosed |
| CN-113508118-B | Fused tricyclic compounds useful as anticancer agents | 阿斯利康(瑞典)有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-3935060-B1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2023-11-15 | — | — | EP | disclosed |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | ASTRAZENECA UK LIMITED (GB) | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410187-B2 | Fused tricyclic compounds useful as anticancer agents | MCL1, TP53, CCNA2 | KAT7 1949/4885PAK1 2316/4885KAT6A 3680/4885 |
| US-20220204527-A1 | FUSED TRICYCLIC COMPOUNDS USEFUL AS ANTICANCER AGENTS | MCL1, TP53, CCNA2 | KAT7 1949/4885PAK1 2316/4885KAT6A 3680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.